Navigation Links
Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis

EVRY, France, June 25, 2007 /PRNewswire/ -- Novagali Pharma, an emerging pharmaceutical company specialized in ophthalmology presents positive results of its pivotal phase III clinical trial positive results from the Phase III clinical study of Vekacia(R) in children suffering from Vernal Keratoconjunctivitis (VKC) at the XIV Afro-Asian Congress of ophthalmology (AACO) held from June 20 to 25 2007 in Marrakech (Morocco).

VKC is a severe form of chronic allergic conjunctivitis characterized by ocular discomfort, pain, itching and intense photophobia, which severely debilitates the patients. This rare disease affects mostly children and young adults living in warm climates worldwide. In this orphan disease, it was shown that both symptoms and signs of disease improved in patients receiving Vekacia(R). Furthermore, the tolerability of Vekacia(R) was excellent.

The study was designed as a clinical phase II/III, multicenter, randomized parallel group, double masked, dose ranging, controlled study divided in two treatment periods: (I) a four-week prospective, randomized, multicenter, double-masked, three parallel-group, vehicle-controlled treatment period; and (II) a three-month prospective, multicenter, double-masked treatment period.

The primary objective of Vekacia(R) phase III study was to assess the efficacy of Vekacia(R) 0.05 % and Vekacia(R) 0.1%, administered four times daily, versus a vehicle after a four-week treatment period for patients with VKC. The secondary objectives were to compare the safety and ocular tolerance (objective and subjective) and the long-term safety after four months.

One hundred and eighteen patients (mean age: 8.8) with active bilateral VKC (acute or chronic) were enrolled in the study at over 21 sites in Europe and Mediterranean countries from May 2006 to October 2006. Most patients were suffering from perennial VKC (90 patients, 76.3%) and were presented
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Novagali Pharma Announces Positive Vekacia Clinical Results From Pivotal Phase III Trial in Vernal Keratoconjunctivitis
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:10/27/2014)... , Oct. 27, 2014  In the last few weeks, ... Africa to a worldwide crisis when a ... the virus and died, and two nurses were infected. ... could happen, the use of modern technology, such as electronic health ... unnoticed. This week, InformationWeek Healthcare Editor Alison Diana ...
(Date:10/27/2014)...  OMNIlife science™, Inc. ("OMNI™"), an established medical technology company ... market, announced it will exhibit its, navigated robotic system, ... of Hip and Knee Surgeons (AAHKS) 24th Annual Meeting ... Texas on November 6-9 in Booth #613. ... George B. Cipolletti , President and ...
(Date:10/27/2014)... At the American College of Emergency Physicians ... October 27-30, 2014, Mindray announces the new M9 premium ... technology. A powerful, versatile, and mobile system, the M9 ... for immediate clinical management and decision-making. ... emergency and critical care medicine has a significant impact ...
Breaking Medicine Technology:EHRs in the Age of Ebola: Discuss on InformationWeek 2EHRs in the Age of Ebola: Discuss on InformationWeek 3OMNIlife science to Exhibit at American Association of Hip and Knee Surgeons 24th Annual Meeting in Dallas November 6-9 2OMNIlife science to Exhibit at American Association of Hip and Knee Surgeons 24th Annual Meeting in Dallas November 6-9 3Mindray Introduces Premium Point-of-Care Ultrasound System at ACEP 2
... Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) announced today that it has ... regained compliance with the $1.00 minimum bid price requirement for continued ... , , ... Company that the bid price of its common stock had closed at less ...
... 26 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that ... on the drugs in Isis, development pipeline.  The second call of the series ... April 28, 2010 at 12:00 p.m. ET .  This call will ... , , ...
Cached Medicine Technology:Catalyst Pharmaceutical Partners Regains Compliance with NASDAQ Minimum Bid Price Rule 2Isis Pharmaceuticals to Discuss Its Metabolic Franchise in a Conference Call on Wednesday, April 28 2Isis Pharmaceuticals to Discuss Its Metabolic Franchise in a Conference Call on Wednesday, April 28 3
(Date:10/30/2014)... new treatments for injuries and damage to the joints, ... example, is a hard material that caps the ends ... Davis biomedical engineers, exploring ways to toughen up engineered ... report new developments this week in the journal ... "The problem with engineered tissue is that the mechanical ...
(Date:10/30/2014)... group at the DFG Research Center for Regenerative Therapies ... (CRTD) demonstrated for the first time the in vitro ... dimensions from mouse embryonic stem cells. Correct spatial organization ... dorsal/ventral axis was observed., This study has been published ... Reports " on 30.10.2014 ., For many years Elly ...
(Date:10/30/2014)... Timothy, InstaKNOT’s 4-year-old CEO, plans ... that you are never too young to give back ... and Carl at the 2013 Santa Arriving By Helicopter ... Chamber of Commerce. Tracey gave Timothy a special tour ... his real fireman’s hat, and extending an offer to ...
(Date:10/30/2014)... Diego, Calif. (PRWEB) October 30, 2014 ... longer mutually exclusive concepts in the medical-grade skin ... on the development of uniquely potent topical dermatological ... Health System ( http://www.RefinitySkinScience.com ) with patented COSMEDERM®-7 ... available glycolic acid concentrations (50% and 70%) and ...
(Date:10/30/2014)... Paramount Rx, a full-service prescription benefits ... to help people save money through its innovative discount ... prescription drugs in the new health care system, the ... bridge the relationship between consumers, businesses and the pharmacy ... people face today with medical costs is the rising ...
Breaking Medicine News(10 mins):Health News:Making lab-grown tissues stronger 2Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3
... Md., Nov. 9 Human Genome Sciences,Inc. (Nasdaq: ... JMP,Securities Sector Focus Conference will be webcast and may ... ) A member of Human Genome Sciences, ... on Tuesday, November 13, 2007 at 4:30 pm Eastern,Time. ...
... Calif., Nov. 9 Masimo (Nasdaq: MASI ),the ... Perfusion,pulse oximetry, announced today that the Pricing Committee of ... plan. "This plan is designed to enhance the ... control of the company,that do not offer an adequate ...
... SGP ) will provide a live audio webcast of ... chief financial,officer, at the 2007 Credit Suisse Health Care ... a.m. (MST) (1 p.m. EST). A live audio ... to,the Investor Relations section of the Schering-Plough corporate Web ...
... The American Stock Exchange LLC(R),(Amex(R)) announced today its final ... Health Sciences, Inc. from listing on the,Exchange, and filed ... from,listing with the Securities and Exchange Commission (the "SEC"). ... postponed by,the SEC. Pursuant to its rules, the ...
... CHICAGO (November 9, 2007) A gender difference exists ... they evaluate the factors that may influence their career ... in the November issue of the Journal of the ... a significantly higher percentage of women than men were ...
... from the University of Alabama at Birmingham (UAB) ... common anti-HIV drugs can prevent HIV-positive pregnant women ... drugs, potentially improving future treatment options., Providing tenofovir ... the extent of resistance to non-nucleoside reverse transcriptate ...
Cached Medicine News:Health News:Masimo Corporation Adopts Stockholder Rights Plan 2Health News:Masimo Corporation Adopts Stockholder Rights Plan 3Health News:Survey shows gender differences are factor when surgeons in training choose a subspecialty 2Health News:HIV drug resistance risk in mothers reduced by combination of common drugs 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: